The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Claims

10 · 2 independent · depth 3

10 granted claims

›1.independentAn isolated antibody binding to human CSF-1R, whereinnthe heavy chain variable domain comprises SEQ ID NO:39 and the light chain variable domain compr…+7

›2.independentAn isolated antibody binding to human CSF-1R, whereinnthe heavy chain variable domain comprises a CDR3 region comprising SEQ ID NO: 33, a CDR2 region …+1

Classifications

3 codes

IPC · International Patent Classification

Section A — Human necessities

A61K39/395

USPC · US Patent Classification

424/133.1530/387.1

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this patent are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoom

USPTOApplicanthover for detail · click to open

Pendency

4.0 y

1,456 days filing → grant

Office actions

after a restriction

Responses

2 RCE

Examiner

Meera Natarajan

art unit —

Law firm

Law firm · Log in to unlock

Citations: 178 back · 0 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Term & fees

See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.

Priority chain

1 priority documents

›Priority documents — 1

Type	Document	Date
related publication	US 20110165156 A1	7 Jul 2011

Validity challenges

See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.

Citations

See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.